GlassScriptPhysician profile
Xingyue He
NPI 1740237692
$18,853.57
in general payments reported to CMS, 2019-2025
17 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.24 · 2020: $1,605 · 2021: $1,516 · 2022: $5,833 · 2024: $9,747 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,980 · Consulting Fee: $2,420 · Travel and Lodging: $888 · Food and Beverage: $460 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,980.00 |
| Consulting Fee | $2,420.00 |
| Travel and Lodging | $887.79 |
| Food and Beverage | $459.52 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $7,133.96 | 2024 | |
| Kite Pharma, INC. | $2,986.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $2,344.99 | 2024 | |
| Servier Pharmaceuticals LLC | $1,760.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $1,605.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $990.00 | 2021 | |
| Daiichi Sankyo INC. | $550.00 | 2022 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Sobi, INC | $200.00 | 2024 | |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Genzyme Corporation | $68.36 | 2024 | |
| Janssen Biotech, INC. | $31.52 | 2019-2021 | |
| Incyte Corporation | $21.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.40 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Myriad Genetic Laboratories, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xingyue He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.